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cu.2012.Abstract Aim: To investigate the effects of metoclopramide, domperidone and erythromycin on
blood glucose and serum insulin levels, gastrointestinal motility and carbohydrate absorption in
streptozotocin-induced diabetic mice treated with glimepiride.
Design and methods: Effects of the individual as well as combined drugs were studied in diabetic
mice via estimation of the blood glucose and serum insulin levels, small intestinal transit, gastric
emptying, xylose and glucose absorption tests. Diabetic groups were treated with glimepiride
(10 mg/kg p.o.), metoclopramide (20 mg/kg p.o.), domperidone (20 mg/kg p.o.) or erythromycin
(6 mg/kg p.o.) individually or in combination.
Results: The test prokinetic drugs metoclopramide (20 mg/kg), domperidone (20 mg/kg) and eryth-
romycin (6 mg/kg)were effective in decreasing small intestinal transit, enhancing gastric emptying and
increasing xylose absorption from theGIT in STZ-induced diabeticmice as compared to diabetic con-
trol value.Metoclopramide or erythromycin potentiated the effect of glimepiride (10 mg/kg) on blood
glucose level and serum insulin level after repeated dose administration in diabetic mice. Glimepiride
(10 mg/kg) signiﬁcantly decreased small intestinal transit and enhanced gastric emptying in diabetic
mice as compared to the diabetic control group. Administration of metoclopramide, domperidone
or erythromycin with glimepiride partially antagonized the action of glimepiride on small intestinal
transit and gastric emptying in diabetic mice. Administration of metoclopramide, domperidone or
erythromycin along with glimepiride signiﬁcantly increased xylose and glucose absorption as com-
pared to the glimepiride treated group.846288.
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24 M.A. Fouad et al.Conclusion: Use of metoclopramide, domperidone or erythromycin with glimepiride may guard
against the risk of gastrointestinal motility disturbance associated with glimepiride treated diabetic
patients and may enhance the absorption of carbohydrates. The dose of glimepiride may be safely
decreased when combined with erythromycin or metoclopramide.
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Diabetes mellitus is the most common cause of gastroparesis
and disturbed gastric and small intestine motility. Delayed gas-
tric emptying of liquid and solid food in patients with type 1
and type 2 diabetes occurs in approximately 50% of the pa-
tients.1 Impaired function of the gastrointestinal tract related
to diabetes mellitus results from diabetic autonomic neuropa-
thy, impaired sensory innervation and a direct effect of chronic
hyperglycemia.42 Current clinical practice to prevent and treat
diabetes involves the use of agents such as insulin and oral
hypoglycemic drugs, but despite these remedies, large numbers
of patients are still suffering from diabetic neuropathy repre-
sented in gastroparesis22 and hypoglycemia associated with
sulfonylurea therapy.
Searching for therapeutic interventions such as prokinetic
drugs that will improve the speciﬁc alterations associated with
diabetic autonomic neuropathy represents the most important
aim of the present study. It deemed of interest to investigate
the possible drug–drug interactions, which may develop from
the co-administration of glimepiride and certain prokinetic
drugs namely metoclopramide, domperidone or erythromycin.
The prokinetic drugs act primarily through neurons since
peristalsis is based on neural reﬂexes. Dopamine antagonists
such as metoclopramide and domperidone49 are used in this
study. Motilides, such as erythromycin, enhance peristalsis
by acting on motilin receptors.26
Motilin receptor is a G protein-coupled receptor that binds
motilin. These receptors are found in the gastrointestinal tract,
and in the central nervous system. Motilin in turn is an intes-
tinal peptide that stimulates the contraction of gut smooth
muscles. Motilin is secreted by endocrine M cells that are
numerous in crypts of the small intestine, especially in the duo-
denum and the jejunum. Because of its ability to stimulate gas-
tric activity, it was named ‘‘Motilin’’.14
In the present study, streptozotocin (STZ)-induced diabetic
mice were treated with glimepiride, prokinetic agents namely
metoclopramide, domperidone or erythromycin individually
and in combination. Acute and subchronic studies were carried
out to determine whether the prokinetic drugs could improve
blood glucose levels and neuropathic changes in diabetic con-
ditions treated with glimepiride. This was achieved by measur-
ing some of the biochemical parameters affected by persistent
hyperglycemia via estimation of blood glucose and serum insu-
lin levels. The gastrointestinal tract motility parameters were
measured represented in small intestinal transit and gastric
emptying. The rate of gastric emptying is an important deter-
minant of carbohydrate absorption and thus of the blood glu-
cose proﬁle. Xylose absorption and glucose absorption tests
were used as representative indices of carbohydrates absorp-
tion changes.2. Materials and Methods
2.1. Drugs and Reagents
Glimepiride (Aventis, Egypt), metoclopramide (Memphis
pharmaceutical co., Cairo, Egypt), domperidone (El Kahira
pharmaceutical co., Cairo, Egypt) and erythromycin ethylsuc-
cinate (Abbott laboratories, Cairo, Egypt) were obtained as
gifts from the mentioned sources. Glucose reagent kit (Bio-
merieux, France), insulin IRMA kit (Immunotech Beckman
Coulter, Czech Republic), streptozotocin (Sigma Aldrich Che-
mie, Germany), phloroglucinol (Sigma Chemical Co., USA)
and D-xylose (Acros Organics, USA) were used. Hydroxypro-
pylmethylcellulose (1%) was used as vehicle to administer
prokinetic drugs. Glimepiride was dispersed in 50 g/l tween
80 in water.
2.2. Animals
Healthy adult male Swiss albino mice weighing 20–30 g were
used in the present study. They were obtained from the animal
house of the research department of Kahira pharmaceutical
company, Cairo, Egypt. All animals were fed standard pellet
chow and had free access to water. They were maintained un-
der controlled laboratory conditions (temperature, humidity)
throughout the study. Experiments were conducted in accor-
dance with the guidelines set by the Animals Health Research
Ethics Training Initiative, Egypt.
2.3. Drug treatments
Control groups received equal volumes of vehicle through cor-
responding routes. The groups included were normal control,
diabetic control, glimepiride 10 mg/kg, metoclopramide
20 mg/kg, domperidone 20 mg/kg and erythromycin 6 mg/kg
alone and in combination. All doses were given orally. The
doses were selected based on the earlier reports and recom-
mended clinical doses.20,30,46 Six main sets of experiments were
carried out. The ﬁrst set of experiments was carried out to
investigate the subchronic effect of 1 week of daily dose of
glimepiride, metoclopramide, domperidone and erythromycin
individually as well as the combination of glimepiride with
each drug in STZ-induced diabetic male mice on blood glucose
and serum insulin levels. The other ﬁve sets of experiments
were carried out to investigate the acute effect of a single dose
of glimepiride, metoclopramide, domperidone and erythromy-
cin individually as well as the combination of glimepiride with
each drug on blood glucose and serum insulin levels, small
intestinal transit, gastric emptying, xylose and glucose
absorption.
Interaction of glimepiride with prokinetic drugs on some of gastrointestinal functions in STZ-induced diabetic mice 252.4. Experimental induction of diabetes
Diabetes mellitus was induced in overnight food deprived mice
by a single intraperitoneal injection of freshly prepared solu-
tion of STZ 100 mg/kg body weight in 0.1 M cold citrate pH
4.5.28 Two weeks following STZ injection, blood samples were
collected from the tail venipuncture of mice and used for the
estimation of blood glucose levels using an advanced Glucom-
eter ACCU-CHEK.45 Overnight food deprived mice with
blood glucose level above 200 mg/dl were selected and used
in the present study.
2.5. Measurement of blood glucose and serum insulin levels
Blood was collected from the retro-orbital venous plexus
according to the method of Cocchetto and Bjornsson.11 Blood
glucose level was measured using an advanced Glucometer
ACCU-CHEK. Serum insulin was estimated by the immuno-
radiometric assay (IRMA) technique,35 using an insulin IRMA
kit. Estimation of blood glucose level was done 2 min before
drug/vehicle administration and 60 min after glimepiride/vehi-
cle administration.
2.6. Small intestinal transit (SIT)
The passage of a charcoal meal through the gastrointestinal
transit in mice is used as the parameter for intestinal motility.31
Overnight food deprived mice were treated either subcutane-
ously 30 min or orally 60 min before administration ofFigure 1 Acute effect of a single oral dose of glimepiride, metoclopr
combination of glimepiride with metoclopramide, domperidone or er
Values represent the mean percentage of diabetic control of eight mice
P< 0.05. aSigniﬁcantly different from the diabetic control value at P<charcoal meal (0.3 ml of a 5% suspension of charcoal in 2%
hydroxypropylmethylcellulose solution). After 20 min, animals
were killed by cervical dislocation. The charcoal marker was
identiﬁed in the small intestine.
Small intestinal transit ðSITÞ
¼ Distance traveled by charcoal
Total length of the small intestine
 1002.7. Gastric emptying
Gastric emptying was determined by the phenol red meth-
od.8,46 Overnight food deprived mice were treated orally
60 min with the test compound prior to oral administration
by gavage of a solution of 1.5% hydroxypropylmethylcellulose
containing 0.05% phenol red as a marker (0.5 ml/mouse). Ani-
mals were sacriﬁced 15 min later by cervical dislocation. The
abdominal cavity was opened, and the cardiac and pyloric
ends of the stomach were clamped, then the stomach was re-
moved and washed with normal saline. The stomach was cut
into pieces and homogenized with 25 ml of 0.1 N NaOH.
The suspension was allowed to settle for 1 h, and then 5 ml
of the supernatant was added to 0.5 ml of 20% trichloroacetic
acid (w/v) and centrifuged at 3000 rpm for 20 min. To one ml
of supernatant 4 ml of 0.5 N NaOH were added. The absor-
bance of this pink color liquid was measured using a spectro-
photometer at 560 nm (Model: Shimatzu 150-20). Phenol red
recovered from animals that were sacriﬁced immediately after
administration of the test meal was used as a standard (0%amide, domperidone and, erythromycin individually as well as the
ythromycin on blood glucose level in STZ-induced diabetic mice.
per group. *Signiﬁcantly different from the normal control value at
0.05. bSigniﬁcantly different from glimepiride value at P< 0.05.
26 M.A. Fouad et al.emptying). Gastric emptying (%) in the 15 min period was cal-
culated according to the following equation:
Gastric emptying ðGEÞ% ¼ 100 ðX Y1  100Þ
X= absorbance of phenol red recovered from the stomach of
animals sacriﬁced 15 min after test meal. Y=mean (n= 5)
absorbance of phenol red recovered from the stomachs of con-
trol animals (killed at 0 min following test meal).
2.8. Oral D-xylose loading test
This test measures intestinal carbohydrate absorption by cal-
culating the plasma concentration of D-xylose after ingestion
of a known amount of D-xylose.23,16 A 30% solution contain-
ing D-xylose (0.8 g/kg body weight) was administrated by oral
gavage to overnight food deprived mice. After 60 min of xylose
administration, blood samples were drawn from the retro-orbi-
tal venous plexus and blood samples were centrifuged at
11,000 rpm for 2 min, plasma xylose concentrations were mea-
sured using a colorimetric assay.
2.9. Glucose absorption
The oral glucose absorption test was used to evaluate intestinal
absorption. The test was carried out according to the method
of Eades et al.15 and Sachin et al.44 After the mice were fasted
for 12 h, the test compound was administered half an hour be-
fore the glucose loading. A 50% glucose solution (2.5 g/kg ofFigure 2 Acute effect of a single oral dose of glimepiride, metoclopr
combination of glimepiride with metoclopramide, domperidone or er
Values represent the mean % of diabetic control of eight mice per
P< 0.05. aSigniﬁcantly different from the diabetic control value at Pbody weight) was orally administered, and blood was taken
from the tail vein at 0 (before the solution load), 30, 60 and
120 min afterward. Blood glucose concentrations were deter-
mined immediately using an ACCU-CHEK. The difference be-
tween the value of the diabetic control group and the diabetic
treated groups represent almost the amount of glucose absorp-
tion from the intestine affected by different drugs used in this
study in addition to other factors. The extent of absorption of
the glucose was estimated using the total area under the curve,
which represents blood glucose level from t0 to t120. AUCtotal is
calculated using the trapezoidal rule from t0 to t120.
2.10. Statistical analysis
All data are expressed as the mean ± standard error with 6–10
mice per group. Statistical analysis was performed using a two
way analysis of variance (ANOVA) followed by the Tukey–
Kramer multiple comparisons test. For all the statistical tests,
the level of signiﬁcance was ﬁxed at P< 0.05.
3. Results
3.1. Acute and subchronic effect of glimepiride and certain
prokinetic drugs individually or combined on blood glucose and
serum insulin levels in diabetic mice
Acute effect of metoclopramide, domperidone or erythromycin
did not affect the action of glimepiride on blood glucose andamide, domperidone and erythromycin individually as well as the
ythromycin on serum insulin level in STZ-induced diabetic mice.
group. *Signiﬁcantly different from the normal control value at
< 0.05. bSigniﬁcantly different from insulin value at P< 0.05.
Figure 3 Subchronic effect of one week daily oral dose administration of glimepiride, metoclopramide, domperidone and erythromycin
individually as well as the combination of glimepiride with metoclopramide, domperidone or erythromycin on blood glucose level in STZ-
induced diabetic mice. Values represent the mean % of diabetic control of eight mice per group. *Signiﬁcantly different from the normal
control value at P< 0.05. aSigniﬁcantly different from the diabetic control value at P< 0.05. bSigniﬁcantly different from glimepiride
value at P< 0.05.
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decrease the blood glucose level and increase the serum insulin
level after 1 week of daily dose administration in STZ-induced
diabetic mice. There is no interaction between glimepiride and
domperidone on blood glucose and serum insulin levels after
1 week of daily dose administration in diabetic mice. Metoclo-
pramide or erythromycin potentiated the effect of glimepiride
on blood glucose level and serum insulin level after 1 week
of daily dose administration in diabetic mice (Figs. 3 and 4).
3.2. Acute effect of glimepiride and certain prokinetic drugs
individually or combined on small intestinal transit (SIT) and
gastric emptying (GE) in diabetic mice
Induction of diabetes in mice signiﬁcantly (p< 0.05) increased
SIT and delayed gastric emptying as compared to the normal
control group. Glimepiride signiﬁcantly (p< 0.05) decreased
SIT and increased GE in diabetic mice as compared to the dia-
betic control group. The test prokinetic drugs i.e. metoclopra-
mide (20 mg/kg), domperidone (20 mg/kg) and erythromycin
(6 mg/kg) signiﬁcantly (p< 0.05) decreased SIT and increased
GE in the diabetic mice. Administration of metoclopramide,
domperidone or erythromycin along with glimepiride signiﬁ-
cantly (p< 0.05) antagonized the effect of each other on small
intestinal transit in diabetic mice and the net results tend to be
normalized (Table 1). Combination of prokinetics i.e. metoclo-pramide, domperidone or erythromycin with glimepiride
(10 mg/kg) signiﬁcantly (p< 0.05) antagonized the action of
glimepiride on gastric emptying (Table 1).
3.3. Acute effect of glimepiride and certain prokinetic drugs
individually or combined on oral D-xylose absorption test in
STZ-induced diabetic mice
The amount of xylose absorbed from the GIT signiﬁcantly
(p< 0.05) decreased in the diabetic mice as compared to nor-
mal control group. Glimepiride (10 mg/kg), metoclopramide
(20 mg/kg), domperidone (20 mg/kg) and erythromycin
(6 mg/kg) signiﬁcantly (p< 0.05) increased xylose absorption
in the diabetic mice compared with the diabetic control mice.
Administration of prokinetic drugs i.e. metoclopramide, dom-
peridone or erythromycin along with glimepiride signiﬁcantly
(p< 0.05) increased xylose absorption (Fig. 5).
3.4. Effect of a single dose of glimepiride and certain prokinetic
drugs individually or combined on oral D-glucose absorption test
in STZ-induced diabetic mice
Administration of glucose load increased the blood glucose le-
vel signiﬁcantly (p< 0.05) after 30 min and 60 min of glucose
loading respectively in STZ-induced diabetic mice (Fig. 6).
STZ signiﬁcantly (p< 0.05) increased the area under the curve
Figure 4 Subchronic effect of 1 week daily oral dose administration of glimepiride, metoclopramide, domperidone and erythromycin
individually as well as the combination of glimepiride with metoclopramide, domperidone or erythromycin on serum insulin level in STZ-
induced diabetic mice. Values represent the mean % of diabetic control of eight mice per group. *Signiﬁcantly different from the normal
control value at P< 0.05. aSigniﬁcantly different from the diabetic control value at P< 0.05. bSigniﬁcantly different from glimepiride
value at P< 0.05.
Table 1 Effect of a single dose of glimepiride and prokinetic drugs alone and in combination on percentage of small intestinal transit
and gastric emptying in diabetic mice.
Treatments Small intestinal transit (%) Gastric emptying (%)
Normal control (citrate buﬀer) 56.61 ± 2.58 72.50 ± 1.68
Diabetic control STZ (100 mg/kg) 76.90* ± 6.12 55.23* ± 9.30
Glimepiride (10 mg/kg p.o.) 49.09a ± 2.63 89.93*a ± 2.96
Metoclopramide (20 mg/kg p.o.) 50.04a ± 2.42 76.38ab ± 7.61
Glimepiride (10 mg/kg p.o.) +Metoclopramide (20 mg/kg p.o.) 65.14ab ± 3.06 51.71*b ± 4.87
Domperidone (20 mg/kg p.o.) 48.70a ± 4.53 90.92*a ± 4.92
Glimepiride (10 mg/kg p.o.) + Domperidone (20 mg/kg p.o.) 64.44ab ± 1.08 50.68*b ± 5.29
Erythromycin (6 mg/kg p.o.) 43.05a ± 3.50 84.77a ± 2.11
Glimepiride (10 mg/kg p.o.) + Erythromycin (6 mg/kg p.o.) 59.06ab ± 5.95 41.82*b ± 4.21
Values represent the mean %± s.e.m. of eight mice per group.
* Signiﬁcantly different from the normal control value at P< 0.05.
a Signiﬁcantly different from the diabetic control value at P< 0.05.
b Signiﬁcantly different from glimepiride value at P< 0.05.
28 M.A. Fouad et al.(Fig. 7). Glimepiride (10 mg/kg) signiﬁcantly (p< 0.05) de-
creased the blood glucose level after 30 and 60 min of
glucose loading respectively and the effects persisted till
120 min (Fig. 6). Domperidone (20 mg/kg) and erythromycin
(6 mg/kg) produced a signiﬁcant (p< 0.05) increase in blood
glucose level. Administration of metoclopramide, domperi-
done or erythromycin along with glimepiride signiﬁcantly
(p< 0.05) increased glucose absorption as compared to glim-
epiride value (Figs. 6 and 7).4. Discussion
Findings of the present investigation revealed that STZ-in-
duced diabetes resulted in a signiﬁcant increase in small intes-
tinal transit and decrease in gastric emptying. Similar results
were reported by Christopher and Michael10 and Wen-cai
et al.55 in diabetic mice. The mechanisms underlying diabe-
tes-induced increase in the intestinal transit may, in part,
Figure 5 Effect of a single oral dose of glimepiride, metoclopramide, domperidone and erythromycin individually as well as the
combination of glimepiride with metoclopramide, domperidone or erythromycin on oral D-xylose absorption test in STZ-induced diabetic
mice. Values represent the mean % of diabetic control of eight mice per group. *Signiﬁcantly different from the normal control value at
P< 0.05. aSigniﬁcantly different from the diabetic control value at P< 0.05. bSigniﬁcantly different from glimepiride value at P< 0.05.
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receptor activities.5 The observed delay in gastric emptying
could be partially attributed to the decrease in the number of
myenteric neurons in the stomach as a result of diabetes as re-
ported by Fregonesi et al.18 and Anitha et al.4 Similarly, the in-
crease in intestinal transit could be mediated through the same
mechanism.
All of the stomach’s smooth muscle cells have the ability to
produce electric depolarizations ‘‘slow waves’’ from resting po-
tential. These rhythmic contractions are thought to originate in
the non-smooth muscle pacer cells in the interstitial cells of Ca-
jal.38 Gastric emptying is delayed because the number of gas-
tric interstitial cells (ICCs) is markedly diminished in
diabetes.37
Data of the present investigation showed that STZ-induced
diabetes resulted in a signiﬁcant decrease in xylose absorption.
These results are in agreement with those of Fu¨essl19 in dia-
betic patients. The decrease in xylose absorption could be med-
iated via decreasing the rate of gastric emptying which resulted
from elevation in BGL caused by STZ as reported by the pres-
ent study. This explanation coincides with results given by Fra-
ser et al.17. Data of the present study revealed that acute or
repeated daily dose administration of glimepiride for 1 week
showed a signiﬁcant reduction in blood glucose level and rise
in serum insulin level in STZ-induced diabetic mice. Similar re-
sults have been reported by Krauss et al.29
Glimepiride as a sulfonylurea drug binds to speciﬁc recep-
tors on beta cells resulting in closure of potassium ATP chan-
nels and subsequently open calcium channels leading to anincrease in cytoplastic calcium that stimulates insulin release.43
Other studies suggest that glimepiride has a potent extra pan-
creatic effect on glucose metabolism and may directly stimu-
late glucose transport through phospholipid signaling
pathway.48
Glimepiride signiﬁcantly accelerated gastric emptying in
diabetic mice. Similar results have been reported by Antonietta
et al.6 Glimepiride signiﬁcantly decreased small intestinal tran-
sit in diabetic mice. The present ﬁnding is in accordance with
previous studies reported by Villar et al.53 and Christophe
et al.9
The hypoglycemic action of glimepiride is produced
through binding to a receptor located on the plasma mem-
brane adjacent to potassium channels, called SUR (sulfonyl-
urea receptor). SUR activation inhibits ATP-sensitive K+
channels leading to a reduced efﬂux of potassium. The rise
of intracellular potassium concentration which follows creates
a sufﬁcient cellular depolarization to elicit the opening of volt-
age-dependant calcium channels, allowing the inﬂux of cal-
cium from the extracellular ﬂuid. Once inside the cell, the
calcium binds to calmodulin and the calcium–calmodulin com-
plex activates the enzyme, myosin kinase, which catalyzes di-
rect phosphorylation of myosin. The phosphorylation of
myosin allows it to bind to actin, which completes the conver-
sion of potential energy into mechanical work. The action of a
second enzyme, myosin phosphatase, is needed for myosin to
detach itself from the actin so that the contractile cycle can
be repeated. Smooth muscles can contract as long as myosin
kinase is active and fresh ATP is available.12 Sulfonylurea
Figure 6 Effect of a single oral dose of glimepiride, metoclopramide, domperidone and erythromycin individually as well as the
combination of glimepiride with metoclopramide, domperidone or erythromycin on oral d-glucose absorption test in STZ-induced
diabetic mice. Values represent the mean ± s.e.m. of eight mice per group. *Signiﬁcantly different from the normal control value at
P< 0.05. aSigniﬁcantly different from the diabetic control value at P< 0.05. bSigniﬁcantly different from glimepiride value at P< 0.05.
30 M.A. Fouad et al.receptors differently modulate the interstitial cells of Cajal
(ICC) pacemaker Ca2+ activity and smooth muscle
contractility.36
In the present investigation, glimepiride accelerated xylose
absorption and increased glucose absorption in STZ-induced
diabetic mice. The observed results are in agreement with the
ﬁnding of Ba¨hr et al.7 and Sachin et al.44 It is suggested that
acceleration in gastric emptying caused by glimepiride is
responsible for the increase in xylose and glucose absorption.
This action of glimepiride could be attributed to the effect of
glimepiride which increases intestinal glucose uptake, by an
insulin-independent pathway, probably involving an increased
protein expression of GLUT1 and GLUT4.7
In the present study, domperidone (20 mg/kg p.o.) signiﬁ-
cantly decreased small intestinal transit and accelerated gastric
emptying in STZ-induced diabetic mice. Similar results have
been reported by Patterson et al.39 and Suchitra et al.46 This
result is in accordance with the ﬁndings of Edelbroek et al.33
that showed decrease of SIT coincides with acceleration of gas-
tric emptying. The inhibitory effect of domperidone on small
intestinal transit is probably mediated via its action on dopa-
mine since it is a dopamine antagonist.32 Dopamine has an
indirect inhibitory effect via inhibition of cholinergic transmis-
sion in the myenteric plexus, which regulates the gastrointesti-
nal tract. This explanation is in accordance with explanation
given by Tonini et al.50 Combination of domperidone
(20 mg/kg) and glimepiride (10 mg/kg) decreased the action
of glimepiride on small intestinal transit (SIT) and gastric emp-
tying (GE). This indicates the antagonism between the actionsof two drugs on SIT and GE. It is difﬁcult to satisfactorily ex-
plain this action on the bases of the few lectures available on
the two drugs in this respect. Combination of domperidone
and glimepiride increased xylose and glucose absorption from
the intestine as compared to the effect of glimepiride alone in
the diabetic mice.
Metoclopramide in the dose of 20 mg/kg p.o. signiﬁcantly
decreased small intestinal transit in STZ-induced diabetic mice.
This ﬁnding is in harmony with the data of earlier reports.27,54
The current study revealed that metoclopramide signiﬁcantly
accelerated gastric emptying in the diabetic mice. These data
are also in accordance with results given by Allen and Braden.3
It could be suggested that metoclopramide produced its action
through inhibition of presynaptic and postsynaptic D2 recep-
tors, stimulation of presynaptic excitatory 5-HT4 receptors
and/or antagonism of presynaptic inhibition of muscarinic
receptors. The aforementioned results are in accordance with
that given by Valenzuela and Dooley.52
In the present study, metoclopramide signiﬁcantly in-
creased xylose absorption but did not affect glucose absorp-
tion in STZ-induced diabetes. The action of metoclopramide
is mediated via increased plasma concentrations of glucagon
like peptide-1 and glucose dependant insulinotropic polypep-
tides, which are responsible for the delay in glucose absorp-
tion, this action did not affect the rate of xylose absorption.
This ﬁnding is in harmony with that given by Paul et al.40 In
the present study a combination of metoclopramide (20 mg/
kg) and glimepiride (10 mg/kg) increased glucose absorption
as compared to glimepiride alone in the diabetic mice. In this
Figure 7 Effect of a single oral dose of glimepiride, metoclopramide, domperidone and erythromycin individually as well as the
combination of glimepiride with metoclopramide, domperidone or erythromycin on the area under curve (AUC) of blood glucose
concentrations during the oral glucose absorption test in STZ-induced diabetic mice. Values represent the mean ± s.e.m. of eight mice per
group. *Signiﬁcantly different from the normal control value at P< 0.05. aSigniﬁcantly different from the diabetic control value at
P< 0.05. bSigniﬁcantly different from glimepiride value at P< 0.05.
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glimepiride (10 mg/kg) decreased the action of glimepiride on
small intestinal transit and gastric emptying. This indicates
the antagonism between the actions of two drugs on SIT and
GE. The combination of metoclopramide (20 mg/kg) and
glimepiride (10 mg/kg) signiﬁcantly decreased blood glucose
level and increased serum insulin level after 1 week of daily
dose administration in STZ-induced diabetic mice. Metoclo-
pramide potentiated the effect of glimepiride on blood glucose
level and serum insulin level.
Erythromycin, in the dose of 6 mg/kg p.o. signiﬁcantly de-
creased small intestinal transit and accelerated gastric empty-
ing in the diabetic mice. This ﬁnding is consistent with
results of Peeters,41 Edelbroek et al.,33 and Ishii et al.24 These
actions could be mediated through the action of erythromycin
on motilin receptors in the GIT. It is well known that erythro-
mycin acts as a motilin receptor agonist.26 Erythromycin
(6 mg/kg p.o.) signiﬁcantly increased xylose and glucose
absorption in the diabetic mice as compared to the diabetic
control group. These results are in harmony with that given
by Deane et al.13 The action of erythromycin is probably med-
iated via its agonistic activity to motilin receptors, which accel-
erates gastric emptying as reported by Ishii et al.24 The action
of erythromycin on decreasing small intestinal transit and
accelerating gastric emptying may have an important role in
increasing the rate of nutrient absorption.
The combination of erythromycin (6 mg/kg) and glimepi-
ride (10 mg/kg) increased the amount of xylose and glucoseabsorbed from the GIT in the diabetic mice as compared to
the effect of glimepiride alone in the diabetic mice. This com-
bination decreased the action of glimepiride on small intestinal
transit and gastric emptying. This indicates the antagonism be-
tween the actions of the two drugs on SIT and GE. Further-
more, the combination of erythromycin and glimepiride
signiﬁcantly decreased blood glucose level and increased serum
insulin level after 1 week of daily dose administration in STZ-
induced diabetic mice. Erythromycin potentiated the effect of
glimepiride on blood glucose level and serum insulin level. This
result is in accordance with that given by Ishii et al.24 The ac-
tion of erythromycin on glimepiride could be mediated via its
action as a motilin receptor agonist as reported by Ueno
et al.51 In the present study, erythromycin tended to decrease
blood glucose level and increase serum insulin level after
1 week of daily dose administration in STZ-induced diabetic
mice. It is to be noted that motilin controls the cyclic release
of insulin through vagal cholinergic muscarinic pathways as re-
ported by Suzuki et al.47 and Itoh et al.25 found that there are
no motilin receptors in the pancreas. Therefore, the action of
erythromycin on insulin secretion is probably mediated via va-
gal-cholinergic muscarinic pathway stimulation linking to
serotonergic receptors, a common mechanism in the stimula-
tory effect of motilin on muscle contraction in the stomach
and on pancreatic polypeptide secretion from the endocrine
pancreas.34 The action of erythromycin on gastrointestinal
motility in the present study is on discrepancy to some studies
which state that motilin receptors do not exist in rodents. They
32 M.A. Fouad et al.only exist as pseudogenes.21 However, the present results are in
agreement with other studies.2,56 It is suggested that the action
of erythromycin is mediated by binding to central motilin
receptors that might be involved in the regulation of gastric
motility in diabetic rats.5. Conclusion
Metoclopramide and erythromycin potentiate the effect of
glimepiride on blood glucose level and serum insulin level after
repeated dose administration in diabetic mice. The combina-
tion of glimepiride with metoclopramide, domperidone or
erythromycin increases the rate of xylose and glucose absorbed
from the GIT. This leads to a suggestion that this prokinetic
may guard against the risk of severe hypoglycemia associated
with diabetic patients treated with glimepiride. Use of metoclo-
pramide, domperidone or erythromycin with glimepiride may
guard against the risk of gastrointestinal motility disturbance
commonly observed in the diabetic patient treated with glim-
epiride. The use of prokinetics i.e. erythromycin or metoclo-
pramide may be interesting in the clinic in order to decrease
the need for glimepiride in diabetic patients. This needs further
investigations.6. Conﬂict of interest
None.
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